Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial

著者: José A. Vázquez, Peter G. Pappas, Kenneth D Boffard, Fathima Paruk, Paul Bien, Margaret Tawadrous, Eric Ople, Pamela Wedel, Iwona Oborska, Michael R. Hodges - Antimicrobial Agents and Chemotherapy 2023 被引用: 78

Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, single-arm study evaluated FMGX safety and efficacy for treatment of candidemia and/or invasive candidiasis caused by Candida auris .